CNTX

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company, which is engaged in advancing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. It is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.

Wall Street analysts forecast CNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTX is 4.75 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Context Therapeutics Inc revenue for the last quarter amounts to -10.61M USD, decreased -43.26 % YoY.

Context Therapeutics Inc. EPS for the last quarter amounts to -6578864.00 USD, increased 239.00 % YoY.

Context Therapeutics Inc (CNTX) has 12 emplpoyees as of December 15 2025.

Today CNTX has the market capitalization of 95.55M USD.